Bergenin exerts anti-cancer activity in hepatocellular carcinoma via the PI3K/Akt/mTOR and MAPK/ERK pathways

Area of Science:

• Hepatocellular Carcinoma (HCC) Research
• Natural Product Drug Discovery
• Molecular Oncology

Background:

• Hepatocellular carcinoma (HCC) presents significant therapeutic challenges due to limited effective treatment options.
• Bergenin, a natural bioactive compound, has potential as an anti-cancer agent.
• Understanding bergenin's molecular mechanisms against HCC is crucial for therapeutic development.

Purpose of the Study:

• To investigate the anti-tumor effects of bergenin on Hepatocellular Carcinoma (HCC).
• To elucidate the molecular mechanisms underlying bergenin's anti-HCC activity.
• To evaluate bergenin's efficacy in both in vitro and in vivo models.

Main Methods:

• In vitro assays: CCK-8 viability, colony formation, TUNEL, flow cytometry, wound healing, and transwell assays.
• Molecular analyses: apoptosis markers (caspase-3/-9), metastasis proteins (MMP-2/-9), and signaling pathways (PI3K/Akt/mTOR, MAPK/ERK).
• In vivo studies: Xenograft models to assess tumor growth inhibition.

Main Results:

• Bergenin significantly inhibited HCC cell proliferation and colony formation in a dose-dependent manner.
• Apoptosis was induced by bergenin through caspase-3/-9 activation.
• Cell migration and invasion were suppressed via downregulation of MMP-2/-9.
• Tumor growth was significantly inhibited in vivo.
• Bergenin concurrently inhibited PI3K/Akt/mTOR and MAPK/ERK signaling pathways.

Conclusions:

• Bergenin demonstrates potent anti-HCC activity by inhibiting proliferation, inducing apoptosis, and suppressing metastasis.
• The anti-tumor effects are mediated through the dual inhibition of the PI3K/Akt/mTOR and MAPK/ERK signaling pathways.
• Bergenin represents a promising therapeutic candidate for Hepatocellular Carcinoma treatment.